Search
Anumigilimab
go.drugbank.com/drugs/DB16359Investigational[A225626] It has potential applications in various inflammatory conditions such as cystic fibrosis, inflammatory bowel disease, rheumatoid arthritis, and vasculitis.[L27516]
Ammonium molybdate
go.drugbank.com/drugs/DB11128InvestigationalIt is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN).
Synonyms: Molybdenum (as ammonium molybdate)Vicriviroc
go.drugbank.com/drugs/DB06652InvestigationalVicriviroc, also known as SCH 417690 and SCH-D, is currently in clinical trials for the management of HIV-1.
Cediranib
go.drugbank.com/drugs/DB04849InvestigationalIt is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Isatin
go.drugbank.com/drugs/DB02095ExperimentalIsatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids.
Motexafin lutetium
go.drugbank.com/drugs/DB05296InvestigationalMotexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. Motexafin lutetium is a pentadentate ...
Ginsenoside Rb1
go.drugbank.com/drugs/DB06749ExperimentalNutraceuticalGinsenosides have been the target of research, as they are viewed as the active compounds behind the claims of ginseng's efficacy.
Belnacasan
go.drugbank.com/drugs/DB05507InvestigationalVX-765 is currently under clinical development for the treatment of inflammatory and autoimmune conditions, as it blocks the hypersensitive response to an inflammatory stimulus.
Methoxy arachidonyl fluorophosphonate
go.drugbank.com/drugs/DB02465ExperimentalMethoxy arachidonyl fluorophosphonate, commonly referred as MAFP, is an irreversible active site-directed enzyme inhibitor that inhibits nearly all serine hydrolases and serine proteases.
Cetrelimab
go.drugbank.com/drugs/DB15421Investigationalinvestigation in clinical trial NCT03547037 (A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as